Skip to main content

Akero Therapeutics, Inc.

AKRODelisted Dec 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001744659

Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.

13F holders, Q4 2021

Institutional positions in Akero Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
97
−5 vs. Q3 2021
Shares held
35.3M
+7.33M (+26.2%) vs. Q3 2021
Total value
$746.8M
+$120.8M (+19.3%) vs. Q3 2021
New holders
11
30 more added
Sold out
16
33 more reduced

1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AKRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2021: 97 institutions
Q1 2021: 109 institutionsQ2 2021: 97 institutionsQ3 2021: 103 institutionsQ4 2021: 97 institutionsQ1 2022: 103 institutionsQ2 2022: 113 institutionsQ3 2022: 146 institutionsQ4 2022: 162 institutionsQ1 2023: 156 institutionsQ2 2023: 157 institutionsQ3 2023: 181 institutionsQ4 2023: 157 institutionsQ1 2024: 173 institutionsQ2 2024: 153 institutionsQ3 2024: 168 institutionsQ4 2024: 191 institutionsQ1 2025: 240 institutionsQ2 2025: 257 institutionsQ3 2025: 265 institutionsQ4 2025: 5 institutionsQ1 2026: 1 institutionQ2 2026: 1 institution
Value heldQ4 2021: $746.8M
Q1 2021: $913.6MQ2 2021: $684.2MQ3 2021: $626.0MQ4 2021: $746.8MQ1 2022: $499.2MQ2 2022: $329.6MQ3 2022: $1.59BQ4 2022: $2.66BQ1 2023: $1.84BQ2 2023: $2.63BQ3 2023: $2.90BQ4 2023: $1.38BQ1 2024: $1.85BQ2 2024: $1.68BQ3 2024: $2.09BQ4 2024: $2.06BQ1 2025: $3.50BQ2 2025: $4.92BQ3 2025: $4.34BQ4 2025: $533.0KQ1 2026: $0Q2 2026: $0
Institutions holding AKRO and their total value by quarter
QuarterHoldersValue
Q2 20261$0
Q1 20261$0
Q4 20255$533.0K
Q3 2025265$4.34B
Q2 2025257$4.92B
Q1 2025240$3.50B
Q4 2024191$2.06B
Q3 2024168$2.09B
Q2 2024153$1.68B
Q1 2024173$1.85B
Q4 2023157$1.38B
Q3 2023181$2.90B
Q2 2023157$2.63B
Q1 2023156$1.84B
Q4 2022162$2.66B
Q3 2022146$1.59B
Q2 2022113$329.6M
Q1 2022103$499.2M
Q4 202197$746.8M
Q3 2021103$626.0M
Q2 202197$684.2M
Q1 2021109$913.6M

Institutions, Q4 2021

Shares, value and share of portfolio for each institution holding Akero Therapeutics, Inc.; share changes are against Q3 2021.

Institutions holding AKRO in Q4 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Stansberry Asset Management, LLC0$00.00%−21,883−100.0%Sold out
Winton Group Ltd0$00.00%−16,330−100.0%Sold out
Simplex Trading, LLC0$00.00%−11,642−100.0%Sold out
Parametric Portfolio Associates LLC0$00.00%−9,254−100.0%Sold out
Nan Fung Group Holdings Ltd0$00.00%−3,470−100.0%Sold out
Penserra Capital Management LLC0$00.00%−800−100.0%Sold out
Point72 Hong Kong Ltd0$00.00%−650−100.0%Sold out
Evolution Wealth Advisors, LLC0$00.00%−211−100.0%Sold out
Brewin Dolphin Ltd0$00.00%−100−100.0%Sold out
Johnson Midwest Financial, LLC0$00.00%−103−100.0%Sold out
Toth Financial Advisory Corp0$00.00%−50−100.0%Sold out
Signaturefd, LLC0$00.00%−48−100.0%Sold out
Geneos Wealth Management Inc.0$00.00%−50−100.0%Sold out
First Mercantile Trust Co––––Not filed